• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.

作者信息

Potere Nicola, Di Nisio Marcello, Cibelli Donatella, Scurti Rosa, Frattari Antonella, Porreca Ettore, Abbate Antonio, Parruti Giustino

机构信息

Department of Medical, Oral and Biotechnological Sciences, "G D'Annunzio" University, Chieti, Italy.

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

出版信息

Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9.

DOI:10.1136/annrheumdis-2020-218243
PMID:32647027
Abstract
摘要

相似文献

1
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎及炎症风暴：一项病例对照研究
Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9.
2
Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.托珠单抗治疗成人重症 COVID-19 肺炎患者：一项单中心队列研究。
J Med Virol. 2021 Feb;93(2):831-842. doi: 10.1002/jmv.26308. Epub 2020 Jul 27.
3
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere .关于Potere的“皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎和炎症反应过度：一项病例对照研究”的通信
Ann Rheum Dis. 2022 Oct;81(10):e194. doi: 10.1136/annrheumdis-2020-218693. Epub 2020 Sep 1.
4
The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.托珠单抗给药时机对中重度 COVID-19 患者的重要性：单中心经验病例系列。
Acta Med Indones. 2021 Jul;53(3):319-325.
5
Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study'.关于“皮下注射托珠单抗阻断白细胞介素-6受体治疗重症新型冠状病毒肺炎和炎症反应过度：病例对照研究”的通信
Ann Rheum Dis. 2023 Aug;82(8):e182. doi: 10.1136/annrheumdis-2020-218836. Epub 2020 Sep 21.
6
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.白细胞介素-6 受体阻滞剂托珠单抗皮下注射可改善 COVID-19 患者的凝血活性。
Eur J Intern Med. 2021 Jan;83:34-38. doi: 10.1016/j.ejim.2020.10.020. Epub 2020 Nov 3.
7
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.COVID-19 严重急性呼吸窘迫综合征中静脉注射托珠单抗阻断白细胞介素-6 受体：128 例患者回顾性病例对照生存分析。
J Autoimmun. 2020 Nov;114:102511. doi: 10.1016/j.jaut.2020.102511. Epub 2020 Jul 8.
8
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.呼吸功能障碍预测新冠肺炎重症肺炎和过度炎症患者对白细胞介素-1 和白细胞介素-6 阻断的反应。
Front Immunol. 2021 Apr 29;12:675678. doi: 10.3389/fimmu.2021.675678. eCollection 2021.
9
Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.托珠单抗治疗重症 COVID-19 肺炎恶化：倾向评分分析。
J Clin Immunol. 2021 Feb;41(2):303-314. doi: 10.1007/s10875-020-00911-6. Epub 2020 Nov 14.
10
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.托珠单抗治疗 COVID-19 住院患者：临床结局、炎症标志物动力学和安全性。
J Med Virol. 2021 Apr;93(4):2270-2280. doi: 10.1002/jmv.26674. Epub 2020 Nov 22.

引用本文的文献

1
Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.细胞因子风暴的前沿与热点演变：2004年至2022年的文献计量分析
Heliyon. 2024 May 10;10(10):e30955. doi: 10.1016/j.heliyon.2024.e30955. eCollection 2024 May 30.
2
Tissue factor in COVID-19-associated coagulopathy.COVID-19 相关凝血病中的组织因子。
Thromb Res. 2022 Dec;220:35-47. doi: 10.1016/j.thromres.2022.09.025. Epub 2022 Oct 1.
3
Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.
用于管理 COVID-19 危重症患者的免疫调节治疗：一项叙述性综述。
World J Crit Care Med. 2022 Jul 9;11(4):269-297. doi: 10.5492/wjccm.v11.i4.269.
4
Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis.托珠单抗对成人新型冠状病毒肺炎的影响：一项荟萃分析。
Front Med (Lausanne). 2022 Mar 30;9:838904. doi: 10.3389/fmed.2022.838904. eCollection 2022.
5
Increased Circulating Cytokines Have a Role in COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-Analysis.循环细胞因子增加在新冠病毒疾病严重程度和死亡中起作用，在男性中影响更显著：一项系统评价和荟萃分析
Front Pharmacol. 2022 Feb 14;13:802228. doi: 10.3389/fphar.2022.802228. eCollection 2022.
6
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
7
Targeting the NLRP3 inflammasome in cardiovascular diseases.针对心血管疾病中的 NLRP3 炎性小体。
Pharmacol Ther. 2022 Aug;236:108053. doi: 10.1016/j.pharmthera.2021.108053. Epub 2021 Dec 11.
8
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.托珠单抗治疗重症 COVID-19 的获益和危害：系统评价和荟萃分析。
Pharmacotherapy. 2021 Nov;41(11):884-906. doi: 10.1002/phar.2627. Epub 2021 Oct 1.
9
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.COVID-19 住院患者使用托珠单抗时机的影响。
Respir Care. 2021 Dec;66(12):1805-1814. doi: 10.4187/respcare.08779. Epub 2021 Sep 21.
10
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.托珠单抗在住院的中重度 COVID-19 肺炎患者中联合或不联合皮质类固醇的实际应用：一项回顾性队列研究。
PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.